These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 32517661)

  • 1. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
    Amin S; Baine M; Meza J; Lin C
    BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database.
    Amin S; Baine M; Meza J; Alam M; Lin C
    Radiat Oncol; 2020 Jun; 15(1):139. PubMed ID: 32493354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
    Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
    Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
    He J; Blair AB; Groot VP; Javed AA; Burkhart RA; Gemenetzis G; Hruban RH; Waters KM; Poling J; Zheng L; Laheru D; Herman JM; Makary MA; Weiss MJ; Cameron JL; Wolfgang CL
    Ann Surg; 2018 Jul; 268(1):1-8. PubMed ID: 29334562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal timing and treatment strategy for pancreatic cancer.
    Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
    J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer.
    Chawla A; Molina G; Pak LM; Rosenthal M; Mancias JD; Clancy TE; Wolpin BM; Wang J
    Ann Surg Oncol; 2020 Apr; 27(4):1191-1200. PubMed ID: 31802297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
    Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
    J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
    Estrella JS; Rashid A; Fleming JB; Katz MH; Lee JE; Wolf RA; Varadhachary GR; Pisters PW; Abdalla EK; Vauthey JN; Wang H; Gomez HF; Evans DB; Abbruzzese JL; Wang H
    Cancer; 2012 Jan; 118(1):268-77. PubMed ID: 21735446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Immunotherapy after Resection of Pancreatic Cancer.
    Tran TB; Maker VK; Maker AV
    J Am Coll Surg; 2019 Jul; 229(1):19-27.e1. PubMed ID: 30742911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nodal downstaging as a treatment goal for node-positive pancreatic cancer.
    Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS
    Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma.
    Zheng L; Ding D; Edil BH; Judkins C; Durham JN; Thomas DL; Bever KM; Mo G; Solt SE; Hoare JA; Bhattacharya R; Zhu Q; Osipov A; Onner B; Purtell KA; Cai H; Parkinson R; Hacker-Prietz A; Herman JM; Le DT; Azad NS; De Jesus-Acosta AMC; Blair AB; Kim V; Soares KC; Manos L; Cameron JL; Makary MA; Weiss MJ; Schulick RD; He J; Wolfgang CL; Thompson ED; Anders RA; Sugar E; Jaffee EM; Laheru DA
    Clin Cancer Res; 2021 Mar; 27(5):1278-1286. PubMed ID: 33277370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Association of the Sequence of Immunotherapy With the Survival of Unresectable Pancreatic Adenocarcinoma Patients: A Retrospective Analysis of the National Cancer Database.
    Amin S; Baine MJ; Meza JL; Lin C
    Front Oncol; 2020; 10():1518. PubMed ID: 32983998
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma.
    Xie H; Liu J; Yin J; Ogden JR; Mahipal A; McWilliams RR; Truty MJ; Bekaii-Saab TS; Petersen GM; Jatoi A; Hubbard JM; Ma WW
    Oncologist; 2020 Nov; 25(11):e1681-e1690. PubMed ID: 32663355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of chemotherapy sequencing on resectable pancreatic cancer by stage.
    Vega EA; Kutlu OC; Salehi O; Alarcon SV; Abudalou M; Kozyreva O; Krishnan S; Lee D; Freeman R; Conrad C
    Surg Oncol; 2022 Mar; 40():101694. PubMed ID: 34973593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy.
    Swords DS; Francis SR; Lloyd S; Garrido-Laguna I; Mulvihill SJ; Gruhl JD; Christensen MC; Stoddard GJ; Firpo MA; Scaife CL
    J Gastrointest Surg; 2019 Jul; 23(7):1401-1413. PubMed ID: 30187332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy versus chemoradiation in high-risk pancreatic adenocarcinoma: A propensity score-matched analysis.
    Raoof M; Blakely AM; Melstrom LG; Lee B; Warner SG; Chung V; Singh G; Chen YJ; Fong Y
    Cancer Med; 2019 Oct; 8(13):5881-5890. PubMed ID: 31414566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
    Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor.
    Amin S; Baine M; Meza J; Alam M; Lin C
    Clin Transl Radiat Oncol; 2020 Sep; 24():34-40. PubMed ID: 32613090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.